Principal Financial Group Inc Aurinia Pharmaceuticals Inc. Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$5.32 - $7.33 $63,579 - $87,600	-11,951 Reduced 50.66%	11,641 $85,000
Q2 2024 Jul 29, 2024	SELL	$4.81 - $5.78 $56,166 - $67,493	-11,677 Reduced 33.11%	23,592 $134,000
Q1 2024 Apr 29, 2024	BUY	$4.93 - $9.31 $2,391 - $4,515	485 Added 1.39%	35,269 $176,000
Q4 2023 Feb 07, 2024	BUY	$7.13 - $9.49 $3,864 - $5,143	542 Added 1.58%	34,784 $312,000
Q3 2023 Nov 02, 2023	SELL	$7.77 - $12.27 $7,824 - $12,355	-1,007 Reduced 2.86%	34,242 $266,000
Q2 2023 Aug 07, 2023	SELL	$8.96 - $11.69 $29,057 - $37,910	-3,243 Reduced 8.43%	35,249 $341,000
Q1 2023 May 09, 2023	SELL	$5.94 - $11.27 $17,879 - $33,922	-3,010 Reduced 7.25%	38,492 $421,000
Q4 2022 Feb 09, 2023	BUY	$4.11 - $8.14 $90,321 - $178,884	21,976 Added 112.55%	41,502 $179,000
Q3 2022 Nov 09, 2022	SELL	$6.66 - $12.39 $8,558 - $15,921	-1,285 Reduced 6.17%	19,526 $147,000
Q2 2022 Aug 10, 2022	BUY	$8.95 - $12.8 $186,258 - $266,380	20,811 New	20,811 $209,000

209

58.2M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.16B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.